SCHEMBL300079

SCHEMBL300079

CCc1c[nH]c(C(=O)O)n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 4/20 0.35
GABRP O00591 2/20 0.33
GABRD O14764 2/20 0.33
GABRA1 P14867 2/20 0.33
GABRB1 P18505 2/20 0.33
GABRG2 P18507 2/20 0.33
GABRB3 P28472 2/20 0.33
GABRA5 P31644 2/20 0.33
GABRA3 P34903 2/20 0.33
GABRA2 P47869 2/20 0.33
GABRB2 P47870 2/20 0.33
GABRA4 P48169 2/20 0.33
GABRE P78334 2/20 0.33
GABRA6 Q16445 2/20 0.33
GABRG1 Q8N1C3 2/20 0.33
GABRG3 Q99928 2/20 0.33
GABRQ Q9UN88 2/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29740205 0.87 NPC1 (0.39) NPC1RAB9AKMT2AALDH1A1KDM4E
SCHEMBL15555699 0.84 PARP1 (0.30) PARP1
SCHEMBL15284409 0.83 HCAR2 (0.42) HCAR2GABRPGABRDGABRA1GABRB1
SCHEMBL9322943 0.82 HCAR2 (0.44) HCAR2MEN1KMT2AALDH1A1
SCHEMBL29956837 0.82 HCAR2 (0.33) HCAR2LMNACGAS
SCHEMBL5989125 0.80 MAOA (0.33) LMNACGAS
SCHEMBL25971997 0.79 BRD4 (0.39)
SCHEMBL2522318 0.79 GRN (0.37)
SCHEMBL19358702 0.78 ALDH1A1 (0.45) GABRA1GABRB2MEN1NPC1RAB9A
SCHEMBL7826351 0.78 KMT2A (0.44) MEN1KMT2AALDH1A1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3829662-B1 MATERIAL AND METHOD FOR PRODUCING CELL RECEIVING SCAFFOLD LUNG BIOTECHNOLOGY PBC (US) 2025-08-20 EP claimed
EP-2980058-B1 COMPOSITION CONTAINING VINYL-GROUP-CONTAINING COMPOUND TOKYO OHKA KOGYO CO LTD (JP) 2023-05-03 EP claimed
CN-110204494-B Oxygen-substituted phenylimidazole XOR/URAT1 dual inhibitor and preparation and application thereof 华南理工大学 2023-03-24 CN claimed
CN-119856081-A Silicon oxide gel dispersion, transparent low refractive index film, and method for producing silicon oxide gel dispersion 株式会社日本触媒 2025-04-18 CN disclosed
EP-3642199-B1 BENZOFURANS AS IRAK4 MODULATORS HOFFMANN LA ROCHE (CH) 2022-04-27 EP disclosed
EP-3642199-B1 BENZOFURANS AS IRAK4 MODULATORS HOFFMANN LA ROCHE (CH) 2022-04-27 EP disclosed
CN-112334462-A OGA inhibitor compounds 詹森药业有限公司 2021-02-05 CN disclosed
US-10899774-B2 IRAK4 modulators GENENTECH, INC. (US) 2021-01-26 US disclosed
EP-3642199-A1 BENZOFURANS AS IRAK4 MODULATORS H. Hoffnabb-La Roche Ag (CH) 2020-04-29 EP disclosed
US-20200115388-A1 IRAK4 MODULATORS GENENTECH, INC. (US) 2020-04-16 US disclosed
US-20200115388-A1 IRAK4 MODULATORS GENENTECH, INC. (US) 2020-04-16 US disclosed
EP-2321319-B1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES INC (US) 2012-03-14 EP disclosed
US-20110287369-A1 RESIST UNDERLAYER FILM FORMING COMPOSITION CONTAINING SILICON HAVING ANION GROUP NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2011-11-24 US disclosed
EP-2372458-A1 SILICON-CONTAINING RESIST UNDERLAYER FILM FORMATION COMPOSITION HAVING ANION GROUP Nissan Chemical Industries, Ltd. (JP) 2011-10-05 EP disclosed
US-7998950-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2011-08-16 US disclosed
WO-2011064211-A1 BENZENE-FUSED 6-MEMBERED OXYGEN-CONTAINING HETEROCYCLIC DERIVATIVES OF BICYCLIC HETEROARYLS NOVARTIS AG (CH) 2011-06-03 WO disclosed
EP-2321319-A1 ANTIVIRAL COMPOUNDS Gilead Sciences, Inc. (US) 2011-05-18 EP disclosed
CN-101884131-A New fuel cell, and power supply device and electronic device using the fuel cell SONY CORP 2010-11-10 CN disclosed
WO-2010011959-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2010-01-28 WO disclosed
US-20100022508-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10899774-B2 IRAK4 modulators IRAK4, IRAK1, IRAK2 HCAR2 1231/4885GABRP 2689/4885GABRD 2894/4885
US-20200115388-A1 IRAK4 MODULATORS IRAK4, IRAK1, IRAK2 HCAR2 1231/4885GABRP 2689/4885GABRD 2894/4885
US-20110287369-A1 RESIST UNDERLAYER FILM FORMING COMPOSITION CONTAINING SILICON HAVING ANION GROUP SIK2, SRRM2, SRSF7 HCAR2 3394/4885GABRP 4183/4885GABRD 4689/4885
US-20100022508-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 HCAR2 4569/4885GABRP 3673/4885GABRD 4637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.